With pulmonary fibrosis in ARDS representing a life-threating outcome of SARS-CoV-2 infection and serum galectin-3 levels predicting survival in ARDS [144], galectin-3 levels were also measured in COVID-19 patients. This evidence concerns the gene LGALS3 and pulmonary fibrosis.